AIGH Capital Management LLC boosted its position in PolyPid Ltd. (NASDAQ:PYPD - Free Report) by 26.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,342,972 shares of the company's stock after purchasing an additional 277,844 shares during the period. PolyPid comprises 1.4% of AIGH Capital Management LLC's holdings, making the stock its 21st largest position. AIGH Capital Management LLC owned about 8.45% of PolyPid worth $5,828,000 at the end of the most recent quarter.
Separately, BNP Paribas Financial Markets lifted its position in PolyPid by 56.1% during the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company's stock worth $32,000 after acquiring an additional 3,500 shares during the last quarter. Institutional investors own 26.47% of the company's stock.
PolyPid Stock Performance
Shares of PYPD opened at $4.44 on Friday. The stock has a 50 day moving average price of $4.36 and a two-hundred day moving average price of $4.17. The firm has a market capitalization of $84.72 million, a P/E ratio of -1.96 and a beta of 1.41. PolyPid Ltd. has a 52 week low of $2.44 and a 52 week high of $5.12.
PolyPid (NASDAQ:PYPD - Get Free Report) last posted its quarterly earnings data on Wednesday, February 11th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.07). On average, equities analysts forecast that PolyPid Ltd. will post -1.5 earnings per share for the current year.
Wall Street Analyst Weigh In
PYPD has been the subject of several research reports. Wall Street Zen upgraded shares of PolyPid from a "sell" rating to a "hold" rating in a research report on Saturday, March 14th. HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of PolyPid in a research report on Wednesday, February 11th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, PolyPid currently has an average rating of "Moderate Buy" and a consensus price target of $12.25.
Read Our Latest Research Report on PolyPid
PolyPid Profile
(
Free Report)
PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.
Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider PolyPid, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PolyPid wasn't on the list.
While PolyPid currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
